Product Code: PMRREP4427
Report Scope:
Persistence Market Research recently published a new report on the molecular diagnostics in infectious disease testing market for the assessment period of 2022-2032. The report offers a close look at the evolving aspects of the market, and insights into the dynamics impacting market growth. It also focuses on key developments in the market, especially due to the COVID-19 pandemic situation that has affected people, globally. The report includes various macro- and micro-economic factors responsible for a significant impact on market growth.
The report on the molecular diagnostics in infectious disease testing market extensively focuses on the key trends shaping its growth. Additionally, the included opportunity analysis underlines untapped corners for aspiring players. The report also offers a holistic view of the incremental opportunity, which can further help readers make effective decisions for the growth of their businesses.
All stakeholders in the molecular diagnostics in infectious disease testing market can rely on the data offered in this report to make critical decisions. Moreover, the information offered in this report also can help new market entrants expand their bases in this space.
The report elaborates on both, historical and current trends shaping the molecular diagnostics in infectious disease testing market. The performance journey of the market has been drawn and analyzed to make the lucrative opportunities in the market evident to readers. The competitive landscape presented in the report gives a detailed outlook of the profiles of key companies manufacturing molecular diagnostics in infectious disease testing, along with their differential strategies and key focus areas.
Segmentation
The research study offers a detailed market taxonomy, wherein, key segments have been discussed in detail. The market is segmented on the basis of product, application, technique, end user, and region. Every segment is analyzed in detail, and data pertaining to the growth of each segment has been included in the study.
Product
- Instruments and Analyzers
- Assays and Reagents
- Services and Software
Application
- Hepatitis B
- Hepatitis C
- AIDS
- Tuberculosis
- Methicillin-Resistant Staphylococcus Aureus (MRSA)
- Hospital-Acquired Infections
- Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG)
- Human Papillomavirus (HPV) Infection
- Others
Technique
- Polymerase Chain Reaction (PCR)
- Isothermal Nucleic Acid Amplification Technology (INAAT)
- Microarrays
- Next-Generation Sequencing (NGS)
- Hybridization
- Others
End User
- Hospitals
- Private Labs
- Clinics
- Academic Institutes
- Laboratories
- Others
Region
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa
The research report includes a competitive landscape that provides a dashboard view of the key competitors operating in the market. Some of the market players included in this section are Abbott Laboratories, Becton, Dickinson and Company, bioMerieux, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Siemens AG, Veridex, LLC, Luminex Corp., GenMark Diagnostics, Inc., Qiagen N.V., Genomix Biotech, and bioTheranostics.
Key Questions Answered in Report
The research study on the manufacturing molecular diagnostics in infectious disease testing market offers inclusive insights about the growth of the market in the most comprehensive manner. Key insights offered in the report answer some of the most salient questions that assist stakeholders in gauging all the emerging possibilities.
- Will the polymerase chain reaction (PCR) segment continue driving the sales of molecular diagnostics in infectious disease testing market?
- How are technological developments aiding molecular diagnostics in infectious disease testing market?
- Which region is a key contributor to the global molecular diagnostics in infectious disease testing market?
Research Methodology
A unique and promising research methodology forms the base of the market report for the forecast period. This report has been prepared after comprehensive analysis of market events, and riveting insights have been compiled meticulously.
The research methodology is a two-step process comprising primary and secondary research. Key stakeholders, including suppliers, service providers, and experts of several designations, including executive vice presidents, directors, technical advisors, GM marketing professionals, and sales professionals have been interviewed. Secondary sources referred to obtain information include investor presentations of manufacturers, World Bank, IMF, and other credible sources.
Table of Contents
1. Executive Summary
- 1.1. Global Market Overview
- 1.2. Summary of Key Statistics
- 1.3. Summary of Key Findings
- 1.4. Product Evolution Analysis
- 1.5. PMR Analysis and Recommendations
2. Market Overview
- 2.1. Market Coverage/Taxonomy
- 2.2. Market Definition/Scope/Limitations
3. Key Market Trends
- 3.1. Key Trends Impacting the Market
- 3.2. Future Prospects of Molecular Diagnostics in Infectious Disease Testing Industry
- 3.2.1. Factors Fuelling Growth
- 3.2.2. Influx of Brands
- 3.2.3. Innovative Distribution & Marketing Strategies
4. Rules and Regulations
- 4.1. Warning Labels
- 4.2. Regulatory Options for Little Cigars
- 4.2.1. Product Description
- 4.2.2. Health Risks
- 4.2.3. End Usering
- 4.2.4. Minimum Pack Technique Regulatory Gap
- 4.3. Cigar Labeling and Warning Statement Requirements by FDA
- 4.4. Tobacco Control Laws
- 4.4.1. Use of E-Cigarettes is Prohibited
- 4.4.2. Tobacco Advertising is Prohibited in Mass Media
- 4.4.3. Others
- 4.5. Others (During the Course of Study)
5. Global Molecular Diagnostics in Infectious Disease Testing Market Demand Analysis 2017-2021 and Forecast, 2022-2032
- 5.1. Historical Market Volume ('000 Units) Analysis, 2017-2021
- 5.2. Current and Future Market Volume ('000 Units) Projections, 2022-2032
- 5.3. Y-o-Y Growth Trend Analysis
6. Global Molecular Diagnostics in Infectious Disease Testing Market - Pricing Analysis
- 6.1. Pricing Analysis By Product
- 6.2. Global Average Pricing Analysis Benchmark
7. Global Molecular Diagnostics in Infectious Disease Testing Market Demand (in Value or Technique in US$ Mn) Analysis 2017-2021 and Forecast, 2022-2032
- 7.1. Historical Market Value (US$ Mn) Analysis, 2017-2021
- 7.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032
- 7.2.1. Y-o-Y Growth Trend Analysis
- 7.2.2. Absolute $ Opportunity Analysis
8. Market Background
- 8.1. Global Cigar industry Outlook
- 8.1.1. Perception of Cigars
- 8.1.2. Prevalence of Smoking Cigars among Adults
- 8.1.3. Top 10 Cigars & Cigarillo Companies in the World
- 8.2. Macro-Economic Factors
- 8.2.1. GDP Growth Outlook
- 8.2.2. Consumer Spending Outlook
- 8.2.3. GDP Growth Rate Analysis
- 8.2.4. Income Group Population Overview
- 8.2.5. Per Capita Disposable Income
- 8.3. Forecast Factors - Relevance & Impact
- 8.3.1. Top Companies Historical Growth
- 8.3.2. Urbanization Growth Outlook
- 8.3.3. Others
- 8.4. PESTLE Analysis of Global Molecular Diagnostics in Infectious Disease Testing Market
- 8.5. Investment Feasibility Matrix of Molecular Diagnostics in Infectious Disease Testing Market
- 8.6. Porter's Five Forces Analysis of Global Molecular Diagnostics in Infectious Disease Testing Market
- 8.7. Market Dynamics
- 8.7.1. Drivers
- 8.7.2. Restraints
- 8.7.3. Opportunity Analysis
9. Global Molecular Diagnostics in Infectious Disease Testing Market Analysis 2017-2021 and Forecast 2022-2032, By Product
- 9.1. Introduction / Key Findings
- 9.2. Historical Market Size (US$ Mn) and Volume ('000 Units) Analysis by Product, 2017 - 2021
- 9.3. Current and Future Market Size (US$ Mn) and Volume ('000 Units) Analysis and Forecast by Product, 2022 - 2032
- 9.3.1. Instruments and Analyzers
- 9.3.2. Assays and Reagents
- 9.3.3. Services and Software
- 9.4. Market Attractiveness Analysis by Product
10. Global Molecular Diagnostics in Infectious Disease Testing Market Analysis 2017-2021 and Forecast 2022-2032, by Application
- 10.1. Introduction / Key Findings
- 10.2. Historical Market Size (US$ Mn) and Volume ('000 Units) Analysis by Application, 2017 - 2021
- 10.3. Current and Future Market Size (US$ Mn) and Volume ('000 Units) Analysis and Forecast by Application, 2022 - 2032
- 10.3.1. Hepatitis B
- 10.3.2. Hepatitis C
- 10.3.3. AIDS
- 10.3.4. Tuberculosis
- 10.3.5. Methicillin-Resistant Staphylococcus Aureus (MRSA)
- 10.3.6. Hospital-Acquired Infections
- 10.3.7. Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG)
- 10.3.8. Human Papillomavirus (HPV) Infection
- 10.3.9. Others
- 10.4. Market Attractiveness Analysis by Application
11. Global Molecular Diagnostics in Infectious Disease Testing Market Analysis 2017-2021 and Forecast 2022-2032, by Technique
- 11.1. Introduction / Key Findings
- 11.2. Historical Market Size (US$ Mn) and Volume ('000 Units) Analysis by Technique, 2017 - 2021
- 11.3. Current and Future Market Size (US$ Mn) and Volume ('000 Units) Analysis and Forecast by Technique, 2022 - 2032
- 11.3.1. Polymerase Chain Reaction (PCR)
- 11.3.2. Isothermal Nucleic Acid Amplification Technology (INAAT)
- 11.3.3. Microarrays
- 11.3.4. Next-Generation Sequencing (NGS)
- 11.3.5. Hybridization
- 11.3.6. Others
- 11.4. Market Attractiveness Analysis by Technique
12. Global Molecular Diagnostics in Infectious Disease Testing Market Analysis 2017-2021 and Forecast 2022-2032, by End User
- 12.1. Introduction / Key Findings
- 12.2. Historical Market Size (US$ Mn) and Volume ('000 Units) Analysis by Flavor, 2017 - 2021
- 12.3. Current and Future Market Size (US$ Mn) and Volume ('000 Units) Analysis and Forecast by Flavor, 2022 - 2032
- 12.3.1. Hospitals
- 12.3.2. Private Labs
- 12.3.3. Clinics
- 12.3.4. Academic Institutes
- 12.3.5. Laboratories
- 12.3.6. Others
- 12.4. Market Attractiveness Analysis by Flavor
13. Global Molecular Diagnostics in Infectious Disease Testing Market Analysis 2017-2021 and Forecast 2022-2032, by Region
- 13.1. Introduction
- 13.2. Historical Market Size (US$ Mn) and Volume ('000 Units) Analysis by Region, 2017 - 2021
- 13.3. Current Market Size (US$ Mn) and Volume ('000 Units) Analysis and Forecast by Region, 2022 - 2032
- 13.3.1. North America
- 13.3.2. Latin America
- 13.3.3. Europe
- 13.3.4. East Asia
- 13.3.5. South Asia
- 13.3.6. Oceania
- 13.3.7. Middle East and Africa (MEA)
- 13.4. Market Attractiveness Analysis by Region
14. North America Molecular Diagnostics in Infectious Disease Testing Market Analysis 2017-2021 and Forecast 2022-2032
- 14.1. Introduction
- 14.2. Pricing Analysis
- 14.3. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2017 - 2021
- 14.4. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2022 - 2032
- 14.4.1. By Country
- 14.4.1.1. U.S.
- 14.4.1.2. Canada
- 14.4.2. By Product
- 14.4.3. By End User
- 14.4.4. By Application
- 14.4.5. By Technique
- 14.5. Market Attractiveness Analysis
- 14.5.1. By Country
- 14.5.2. By Product
- 14.5.3. By End User
- 14.5.4. By Application
- 14.5.5. By Technique
15. Latin America Molecular Diagnostics in Infectious Disease Testing Market Analysis 2017-2021 and Forecast 2022-2032
- 15.1. Introduction
- 15.2. Pricing Analysis
- 15.3. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2017 - 2021
- 15.4. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2022 - 2032
- 15.4.1. By Country
- 15.4.1.1. Brazil
- 15.4.1.2. Mexico
- 15.4.1.3. Rest of Latin America
- 15.4.2. By Product
- 15.4.3. By End User
- 15.4.4. By Application
- 15.4.5. By Technique
- 15.5. Market Attractiveness Analysis
- 15.5.1. By Country
- 15.5.2. By Product
- 15.5.3. By End User
- 15.5.4. By Application
- 15.5.5. By Technique
16. Europe Molecular Diagnostics in Infectious Disease Testing Market Analysis 2017-2021 and Forecast 2022-2032
- 16.1. Introduction
- 16.2. Pricing Analysis
- 16.3. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2017 - 2021
- 16.4. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2022 - 2032
- 16.4.1. By Country
- 16.4.1.1. Germany
- 16.4.1.2. Italy
- 16.4.1.3. France
- 16.4.1.4. U.K.
- 16.4.1.5. Spain
- 16.4.1.6. Rest of Europe
- 16.4.2. By Product
- 16.4.3. By End User
- 16.4.4. By Application
- 16.4.5. By Technique
- 16.5. Market Attractiveness Analysis
- 16.5.1. By Country
- 16.5.2. By Product
- 16.5.3. By End User
- 16.5.4. By Application
- 16.5.5. By Technique
17. South Asia Molecular Diagnostics in Infectious Disease Testing Market Analysis 2017-2021 and Forecast 2022-2032
- 17.1. Introduction
- 17.2. Pricing Analysis
- 17.3. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2017 - 2021
- 17.4. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2022 - 2032
- 17.4.1. By Country
- 17.4.1.1. India
- 17.4.1.2. Thailand
- 17.4.1.3. Indonesia
- 17.4.1.4. Malaysia
- 17.4.1.5. Rest of South Asia
- 17.4.2. By Product
- 17.4.3. By End User
- 17.4.4. By Application
- 17.4.5. By Technique
- 17.5. Market Attractiveness Analysis
- 17.5.1. By Country
- 17.5.2. By Product
- 17.5.3. By End User
- 17.5.4. By Application
- 17.5.5. By Technique
18. East Asia Molecular Diagnostics in Infectious Disease Testing Market Analysis 2017-2021 and Forecast 2022-2032
- 18.1. Introduction
- 18.2. Pricing Analysis
- 18.3. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2017 - 2021
- 18.4. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2022 - 2032
- 18.4.1. By Country
- 18.4.1.1. China
- 18.4.1.2. Japan
- 18.4.1.3. South Korea
- 18.4.2. By Product
- 18.4.3. By End User
- 18.4.4. By Application
- 18.4.5. By Technique
- 18.5. Market Attractiveness Analysis
- 18.5.1. By Country
- 18.5.2. By Product
- 18.5.3. By End User
- 18.5.4. By Application
- 18.5.5. By Technique
19. Oceania Molecular Diagnostics in Infectious Disease Testing Market Analysis 2017-2021 and Forecast 2022-2032
- 19.1. Introduction
- 19.2. Pricing Analysis
- 19.3. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2017 - 2021
- 19.4. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2022 - 2032
- 19.4.1. By Country
- 19.4.1.1. Australia
- 19.4.1.2. New Zealand
- 19.4.2. By Product
- 19.4.3. By End User
- 19.4.4. By Application
- 19.4.5. By Technique
- 19.5. Market Attractiveness Analysis
- 19.5.1. By Country
- 19.5.2. By Product
- 19.5.3. By End User
- 19.5.4. By Application
- 19.5.5. By Technique
20. Middle East and Africa Molecular Diagnostics in Infectious Disease Testing Market Analysis 2017-2021 and Forecast 2022-2032
- 20.1. Introduction
- 20.2. Pricing Analysis
- 20.3. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2017 - 2021
- 20.4. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2022 - 2032
- 20.4.1. By Country
- 20.4.1.1. GCC Countries
- 20.4.1.2. Northern Africa
- 20.4.1.3. South Africa
- 20.4.1.4. Rest of Middle East and Africa
- 20.4.2. By Product
- 20.4.3. By End User
- 20.4.4. By Application
- 20.4.5. By Technique
- 20.5. Market Attractiveness Analysis
- 20.5.1. By Country
- 20.5.2. By Product
- 20.5.3. By End User
- 20.5.4. By Application
- 20.5.5. By Technique
21. Key Countries' Molecular Diagnostics in Infectious Disease Testing Market Analysis 2022-2032
- 21.1. Introduction
- 21.1.1. Market Value Proportion Analysis, By Key Countries
- 21.1.2. Global Vs. Country Growth Comparison
- 21.2. U.S. Molecular Diagnostics in Infectious Disease Testing Market Analysis
- 21.2.1. By Product
- 21.2.2. By End User
- 21.2.3. By Application
- 21.2.4. By Technique
- 21.3. Canada Molecular Diagnostics in Infectious Disease Testing Market Analysis
- 21.3.1. By Product
- 21.3.2. By End User
- 21.3.3. By Application
- 21.3.4. By Technique
- 21.4. Mexico Molecular Diagnostics in Infectious Disease Testing Market Analysis
- 21.4.1. By Product
- 21.4.2. By End User
- 21.4.3. By Application
- 21.4.4. By Technique
- 21.5. Brazil Molecular Diagnostics in Infectious Disease Testing Market Analysis
- 21.5.1. By Product
- 21.5.2. By End User
- 21.5.3. By Application
- 21.5.4. By Technique
- 21.6. Germany Molecular Diagnostics in Infectious Disease Testing Market Analysis
- 21.6.1. By Product
- 21.6.2. By End User
- 21.6.3. By Application
- 21.6.4. By Technique
- 21.7. Italy Molecular Diagnostics in Infectious Disease Testing Market Analysis
- 21.7.1. By Product
- 21.7.2. By End User
- 21.7.3. By Application
- 21.7.4. By Technique
- 21.8. U.K. Molecular Diagnostics in Infectious Disease Testing Market Analysis
- 21.8.1. By Product
- 21.8.2. By End User
- 21.8.3. By Application
- 21.8.4. By Technique
- 21.9. China Molecular Diagnostics in Infectious Disease Testing Market Analysis
- 21.9.1. By Product
- 21.9.2. By End User
- 21.9.3. By Application
- 21.9.4. By Technique
- 21.10. Japan Molecular Diagnostics in Infectious Disease Testing Market Analysis
- 21.10.1. By Product
- 21.10.2. By End User
- 21.10.3. By Application
- 21.10.4. By Technique
- 21.11. S. Korea Molecular Diagnostics in Infectious Disease Testing Market Analysis
- 21.11.1. By Product
- 21.11.2. By End User
- 21.11.3. By Application
- 21.11.4. By Technique
- 21.12. India Molecular Diagnostics in Infectious Disease Testing Market Analysis
- 21.12.1. By Product
- 21.12.2. By End User
- 21.12.3. By Application
- 21.12.4. By Technique
- 21.13. Australia and New Zealand Molecular Diagnostics in Infectious Disease Testing Market Analysis
- 21.13.1. By Product
- 21.13.2. By End User
- 21.13.3. By Application
- 21.13.4. By Technique
- 21.14. South Africa Molecular Diagnostics in Infectious Disease Testing Market Analysis
- 21.14.1. By Product
- 21.14.2. By End User
- 21.14.3. By Application
- 21.14.4. By Technique
22. Market Structure Analysis
- 22.1. Market Analysis by Tier of Companies (Molecular Diagnostics in Infectious Disease Testing)
- 22.2. Market Concentration
- 22.3. Market Share Analysis of Top Players
- 22.4. Market Presence Analysis
- 22.4.1. By Regional footprint of Players
- 22.4.2. Product foot print by Players
- 22.4.3. Channel Foot Print by Players
23. Competition Analysis
- 23.1. Competition Dashboard
- 23.2. Pricing Analysis by Competition
- 23.3. Competition Benchmarking
- 23.4. Competition Deep Dive
- 23.4.1. Abbott Laboratories
- 23.4.1.1. Overview
- 23.4.1.2. Product Portfolio
- 23.4.1.3. Profitability by Market Segments (Product/Channel/Region)
- 23.4.1.4. Sales Footprint
- 23.4.1.5. Strategy Overview
- 23.4.1.5.1. Marketing Strategy
- 23.4.1.5.2. Product Strategy
- 23.4.1.5.3. Channel Strategy
- 23.4.2. Becton
- 23.4.2.1. Overview
- 23.4.2.2. Product Portfolio
- 23.4.2.3. Profitability by Market Segments (Product/Channel/Region)
- 23.4.2.4. Sales Footprint
- 23.4.2.5. Strategy Overview
- 23.4.2.5.1. Marketing Strategy
- 23.4.2.5.2. Product Strategy
- 23.4.2.5.3. Channel Strategy
- 23.4.3. Dickinson and Company
- 23.4.3.1. Overview
- 23.4.3.2. Product Portfolio
- 23.4.3.3. Profitability by Market Segments (Product/Channel/Region)
- 23.4.3.4. Sales Footprint
- 23.4.3.5. Strategy Overview
- 23.4.3.5.1. Marketing Strategy
- 23.4.3.5.2. Product Strategy
- 23.4.3.5.3. Channel Strategy
- 23.4.4. bioMerieux
- 23.4.4.1. Overview
- 23.4.4.2. Product Portfolio
- 23.4.4.3. Profitability by Market Segments (Product/Channel/Region)
- 23.4.4.4. Sales Footprint
- 23.4.4.5. Strategy Overview
- 23.4.4.5.1. Marketing Strategy
- 23.4.4.5.2. Product Strategy
- 23.4.4.5.3. Channel Strategy
- 23.4.5. Thermo Fisher Scientific Inc.
- 23.4.5.1. Overview
- 23.4.5.2. Product Portfolio
- 23.4.5.3. Profitability by Market Segments (Product/Channel/Region)
- 23.4.5.4. Sales Footprint
- 23.4.5.5. Strategy Overview
- 23.4.5.5.1. Marketing Strategy
- 23.4.5.5.2. Product Strategy
- 23.4.5.5.3. Channel Strategy
- 23.4.6. F. Hoffmann-La Roche Ltd
- 23.4.6.1. Overview
- 23.4.6.2. Product Portfolio
- 23.4.6.3. Profitability by Market Segments (Product/Channel/Region)
- 23.4.6.4. Sales Footprint
- 23.4.6.5. Strategy Overview
- 23.4.6.5.1. Marketing Strategy
- 23.4.6.5.2. Product Strategy
- 23.4.6.5.3. Channel Strategy
- 23.4.7. Siemens AG
- 23.4.7.1. Overview
- 23.4.7.2. Product Portfolio
- 23.4.7.3. Profitability by Market Segments (Product/Channel/Region)
- 23.4.7.4. Sales Footprint
- 23.4.7.5. Strategy Overview
- 23.4.7.5.1. Marketing Strategy
- 23.4.7.5.2. Product Strategy
- 23.4.7.5.3. Channel Strategy
- 23.4.8. Veridex, LLC
- 23.4.8.1. Overview
- 23.4.8.2. Product Portfolio
- 23.4.8.3. Profitability by Market Segments (Product/Channel/Region)
- 23.4.8.4. Sales Footprint
- 23.4.8.5. Strategy Overview
- 23.4.8.5.1. Marketing Strategy
- 23.4.8.5.2. Product Strategy
- 23.4.8.5.3. Channel Strategy
- 23.4.9. Luminex Corp.
- 23.4.9.1. Overview
- 23.4.9.2. Product Portfolio
- 23.4.9.3. Profitability by Market Segments (Product/Channel/Region)
- 23.4.9.4. Sales Footprint
- 23.4.9.5. Strategy Overview
- 23.4.9.5.1. Marketing Strategy
- 23.4.9.5.2. Product Strategy
- 23.4.9.5.3. Channel Strategy
- 23.4.10. GenMark Diagnostics, Inc.
- 23.4.10.1. Overview
- 23.4.10.2. Product Portfolio
- 23.4.10.3. Profitability by Market Segments (Product/Channel/Region)
- 23.4.10.4. Sales Footprint
- 23.4.10.5. Strategy Overview
- 23.4.10.5.1. Marketing Strategy
- 23.4.10.5.2. Product Strategy
- 23.4.10.5.3. Channel Strategy
- 23.4.11. Qiagen N.V.
- 23.4.11.1. Overview
- 23.4.11.2. Product Portfolio
- 23.4.11.3. Profitability by Market Segments (Product/Channel/Region)
- 23.4.11.4. Sales Footprint
- 23.4.11.5. Strategy Overview
- 23.4.11.5.1. Marketing Strategy
- 23.4.11.5.2. Product Strategy
- 23.4.11.5.3. Channel Strategy
- 23.4.12. Genomix Biotech
- 23.4.12.1. Overview
- 23.4.12.2. Product Portfolio
- 23.4.12.3. Profitability by Market Segments (Product/Channel/Region)
- 23.4.12.4. Sales Footprint
- 23.4.12.5. Strategy Overview
- 23.4.12.5.1. Marketing Strategy
- 23.4.12.5.2. Product Strategy
- 23.4.12.5.3. Channel Strategy
- 23.4.13. bioTheranostics
- 23.4.13.1. Overview
- 23.4.13.2. Product Portfolio
- 23.4.13.3. Profitability by Market Segments (Product/Channel/Region)
- 23.4.13.4. Sales Footprint
- 23.4.13.5. Strategy Overview
- 23.4.13.5.1. Marketing Strategy
- 23.4.13.5.2. Product Strategy
- 23.4.13.5.3. Channel Strategy
24. Assumptions and Acronyms Used
25. Research Methodology